DUSA Pharmaceuticals, Inc. Announces Conference Call to Report On Second Quarter Financial Results.Business Editors/Health & Medical Writers WILMINGTON, Mass.--(BW HealthWire)--Aug. 7, 2001 DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. : DUSA) announces that its second quarter earnings will be released on Monday, August 13, 2001 after 4:00 p.m. A conference call will take place at 8:30 a.m. on Tuesday, August 14, 2001. Dr. Geoff Shulman, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and John Mattern, Vice President, Finance and CFO See Chief Financial Officer. will host the call.
Tuesday, August 14, 2001 at 8:30 a.m. EST
If calling from the US or Canada dial the following toll-free
number:
877.461.2814
For International and Toronto callers, dial 416.695.9753
You will also be able to listen to a replay of the conference call
until August 21, 2001 by dialing the following numbers:
North American callers 888.509.0081
Toronto & International callers 416.695.9728
The recorded call will be accessible on our web site after Wednesday, August 15, 2001 at www.dusapharma.com. DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of LEVULAN(R) Photodynamic Therapy (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ) and Photodetection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as LEVULAN(R) to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion